AI PRICE FORECAST
ELV Stock Forecast & AI Price Prediction
Elevance Health · Healthcare · Healthcare Plans
ELV live signal snapshot
Shares of ELV were last at $429.48, down 0.04% on the day, trading 4.7% below its 52-week high of $450.69 and 56.3% above its 52-week low of $274.84. Our AI model's current call on ELV is HOLD, with 71% confidence. The technical signals aren't aligned enough for a directional call yet. The short-term averages are tangled, giving no clean trend signal either way. Its one-month projection is about $420.75, a -2.0% move from the last price.
ELV's 14-day RSI is 44.2 — approaching oversold, suggesting weakening momentum. The MACD indicator trails its signal line, with a histogram of -0.61 pointing to selling pressure. The 50-day moving average ($414.62) sits 10.7% above the 200-day ($374.65) — a "golden cross" structure that typically supports the longer-term uptrend.
21 Wall Street analysts covering ELV put the average price target at $482.38 (range $406.00–$523.00), implying 12.3% upside from the current price. The current recommendation trend leans bullish: 15 Buy/Strong Buy ratings vs 0 Sell/Strong Sell (and 7 Hold).
Live figures from real market data feeds, current as of the last site build. Open the interactive ELV dashboard for numbers updated throughout today's session.
About Elevance Health
Elevance Health, Inc. (ELV) is a healthcare plans company in the healthcare sector, headquartered in Indianapolis, IN, United States. Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. It has a market value of about $92.8 billion and roughly 96,129 full-time employees. With a beta of 0.63, the stock has historically moved less than the overall market.
ELV performance vs. the market
Year to date, ELV has gained 22.5%, ahead of the S&P 500 (+11.4%) and ahead of the healthcare sector fund XLV (+22.1%). Over the past 12 months the stock has gained 41.4%, 29.9 points better than the S&P 500. Its +1.0% move over the past month extends a +7.8% three-month run.
| Period | ELV | Sector (XLV) | S&P 500 |
|---|---|---|---|
| 1 month | +1.0% | +11.4% | −2.3% |
| 3 months | +7.8% | +12.2% | −2.3% |
| Year to date | +22.5% | +22.1% | +11.4% |
| 1 year | +41.4% | +28.3% | +11.5% |
Elevance Health financials at a glance
Elevance Health's most recent quarter (ended Sep 30, 2026) brought in $50.4 billion of revenue and net income of $1.4 billion (a 2.7% net margin). Revenue was up 1.4% from the same quarter a year earlier. The stock trades at a price-to-earnings ratio of 18.2 on trailing earnings of $23.55 per share. Trailing free cash flow was $8.0 billion, and total debt equals 69% of shareholders' equity.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Sep 30, 2026 | $50.4B | $1.4B |
| Jun 30, 2026 | $49.8B | $1.5B |
| Mar 31, 2026 | $49.5B | $1.8B |
| Dec 31, 2025 | $49.3B | $547M |
ELV vs. its peers
ELV's +22.5% this year ranks ahead of 3 of the 5 big healthcare names below. The strongest of the group this year is Humana (HUM, +74.3%).
| Company | Price | YTD | P/E | AI verdict |
|---|---|---|---|---|
| Elevance Health (ELV) | $429.48 | +22.5% | 18.2 | HOLD |
| UnitedHealth Group (UNH) | $402.94 | +22.1% | 23.0 | HOLD |
| CVS Health (CVS) | $89.52 | +12.8% | 10.4 | HOLD |
| The Cigna Group (CI) | $301.45 | +9.5% | 13.3 | HOLD |
| Humana (HUM) | $446.31 | +74.3% | 43.5 | BUY |
| Eli Lilly and (LLY) | $1,437.29 | +33.7% | 46.7 | BUY |
ELV stock: common questions
What is the ELV stock price target?
21 Wall Street analysts put the average 12-month target at $482.38, in a range of $406.00–$523.00, versus a recent price of $429.48. Stock Pulse 247's model projects about $420.75 over the next month.
Is ELV a buy right now?
Our AI model currently rates ELV a HOLD at 71% confidence. Among analysts, 15 rate it Buy or Strong Buy, 7 Hold and 0 Sell. Neither is personal advice — weigh them with your own research and risk tolerance.
How has ELV stock performed this year?
Year to date, ELV has gained 22.5%, ahead of the S&P 500 (+11.4%) and ahead of the healthcare sector fund XLV (+22.1%). Over the past 12 months the stock has gained 41.4%, 29.9 points better than the S&P 500. Its +1.0% move over the past month extends a +7.8% three-month run.
What is ELV's 52-week high and low?
ELV has traded between $274.84 and $450.69 over the past 52 weeks; at $429.48 it is 4.7% below its 52-week high of $450.69 and 56.3% above its 52-week low of $274.84.
What sector is ELV in, and who are its peers?
ELV is in the healthcare sector (healthcare plans). Its largest peers on Stock Pulse 247 include UnitedHealth Group (UNH), CVS Health (CVS), The Cigna Group (CI), Humana (HUM).
How accurate is the ELV forecast?
It's a model estimate from price history, technical indicators and analyst targets, not a guarantee — no model predicts short-term moves reliably. Use it as one input alongside your own research.
How this works: the forecast combines ELV's price history, momentum indicators (RSI, MACD, moving averages), volatility and analyst targets into one estimate. It's a model, not a guarantee.